KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to Hold at Citizens Jmp

KalVista Pharmaceuticals (NASDAQ:KALV) was downgraded by research analysts at Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Several other equities research analysts have also issued reports on KALV. Needham & Company LLC reiterated a “hold” rating on shares of KalVista Pharmaceuticals in a research report on Thursday. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. HC Wainwright lifted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus lifted their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $32.60.

KalVista Pharmaceuticals Trading Down 0.0%

Shares of KalVista Pharmaceuticals stock opened at $26.66 on Wednesday. KalVista Pharmaceuticals has a 1 year low of $9.83 and a 1 year high of $26.76. The firm has a market cap of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a 50 day simple moving average of $18.45 and a two-hundred day simple moving average of $15.72.

Insider Activity

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $83,361.78. Following the transaction, the insider directly owned 138,983 shares of the company’s stock, valued at approximately $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the transaction, the insider directly owned 5,129,340 shares in the company, valued at $86,942,313. This trade represents a 3.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 263,969 shares of company stock valued at $4,536,178. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KALV. The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 818 shares during the period. BNP Paribas Financial Markets increased its stake in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Rhumbline Advisers increased its stake in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of KalVista Pharmaceuticals by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after buying an additional 2,402 shares during the period. Finally, Profund Advisors LLC increased its stake in shares of KalVista Pharmaceuticals by 25.9% in the third quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock worth $154,000 after buying an additional 2,593 shares during the period.

Key KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for about $1.9 billion and to buy shares for $27.00 in cash — the deal highlights Chiesi’s push into rare-disease/HAE treatment Ekterly and is the primary catalyst for the stock’s jump. Chiesi to buy KalVista in $1.9B deal
• Positive Sentiment: Market reaction: shares surged roughly 38–39% on the takeover news and trading volume spiked well above average, reflecting investor demand to capture the cash takeover consideration. KalVista stock surges 39%
• Neutral Sentiment: Trading mechanics: trading in KALV was temporarily halted prior to the announcement for “news pending,” a routine step that precedes major corporate news and can amplify post-release moves. (Company/regulatory filings reflected the halt.)
• Neutral Sentiment: Analyst view: Needham & Company reaffirmed a “hold” rating on KalVista — a reminder some analysts view the takeover price as fair or limited upside beyond the offer. Needham reaffirms hold
• Negative Sentiment: Litigation risk: multiple shareholder-alerts and law-firm investigations (Ademi LLP and Monteverde & Associates) have been announced questioning whether the $27.00 per-share deal is fair and whether fiduciary duties were met — these actions could delay closing, prompt a negotiated price change, or produce settlement costs. Ademi LLP shareholder alert Monteverde investigation

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.